NCT04435054View on ClinicalTrials.gov

Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.

NACompletedINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

October 28, 2023

Study Completion Date

September 11, 2024

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

DIAGNOSTIC_TEST

Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.

"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~\- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."

Trial Locations (3)

Unknown

Centre Hospitalier Universitaire Dijon Bourgogne, Dijon

CHU de Nantes, Nantes

Hôpital Lyon Sud, Pierre-Bénite

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT04435054 - Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology. | Biotech Hunter | Biotech Hunter